139 related articles for article (PubMed ID: 35393232)
1. The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer.
McLoughlin LC; O'Halloran S; Tjong M; Ajib K; Lajkosz K; Ruff H; Lou S; Chung P; Raman S; Kulkarni GS; Zlotta AR; Fleshner NE; Berlin A
Urol Oncol; 2022 Jul; 40(7):346.e9-346.e16. PubMed ID: 35393232
[TBL] [Abstract][Full Text] [Related]
2. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.
Kim PH; Sukhu R; Cordon BH; Sfakianos JP; Sjoberg DD; Hakimi AA; Dalbagni G; Lin O; Herr HW
BJU Int; 2014 Sep; 114(3):354-9. PubMed ID: 24128299
[TBL] [Abstract][Full Text] [Related]
3. Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle-invasive bladder cancer.
Krishnatry R; Maitre P; Kumar A; Telkhade T; Bakshi G; Prakash G; Pal M; Joshi A; Menon S; Murthy V
Cancer Med; 2023 May; 12(10):11305-11314. PubMed ID: 36965102
[TBL] [Abstract][Full Text] [Related]
4. Conditional survival of trimodal therapy for nonmetastatic muscle-invasive bladder cancer: A SEER database analysis.
Shangguan W; Hu J; Xie Y; Chen Z; Zhong Q; Zheng Z; Zhu D; Zhang Y; Yang J; Han J; Xie W
Cancer Med; 2022 Jun; 11(12):2356-2365. PubMed ID: 35301806
[TBL] [Abstract][Full Text] [Related]
5. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
6. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
[TBL] [Abstract][Full Text] [Related]
7. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
[TBL] [Abstract][Full Text] [Related]
9. Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis.
Ajib K; Berjaoui MB; Herrera-Caceres J; Nason G; Tan GH; Tjong MC; Lajkosz K; Sridhar S; Fleshner NE; Zlotta AR; Catton C; Berlin A; Chung P; Kulkarni GS
Urol Oncol; 2021 Dec; 39(12):835.e1-835.e7. PubMed ID: 34134928
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive studies may have potential to replace cystoscopy in non-muscle invasive bladder cancer follow-up.
Lee J; Heo JE; Kang SK; Lee KS; Han H; Jang WS; Choi YD
Sci Rep; 2022 Dec; 12(1):21677. PubMed ID: 36522359
[TBL] [Abstract][Full Text] [Related]
12. Morphologic alterations post trimodal therapy in muscle-invasive urothelial carcinoma: understanding the impact of post-treatment changes on the pathological interpretation and their potential clinical correlates.
Evaristo G; Khadang B; Kool R; Marcq G; Farag MS; Kassouf W; Brimo F
Hum Pathol; 2022 Aug; 126():2-8. PubMed ID: 35490858
[TBL] [Abstract][Full Text] [Related]
13. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
14. Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided?
Smith PJ; Lotan Y; Raj GV; Sagalowsky AI; Margulis V
Cytopathology; 2014 Apr; 25(2):108-11. PubMed ID: 23551700
[TBL] [Abstract][Full Text] [Related]
15. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.
de Jong FC; Iflé IG; van der Made AC; Kooper D; de Jong JJ; Franckena M; Zuiverloon TCM; van Criekinge W; Incrocci L; Zwarthoff EC; Boormans JL
Eur Urol Open Sci; 2024 Apr; 62():131-139. PubMed ID: 38496820
[TBL] [Abstract][Full Text] [Related]
16. Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?
Kool R; Marcq G; El-Achkar A; Mansure JJ; Vanhuyse M; Aprikian A; Tanguay S; Cury FL; Brimo F; Souhami L; Kassouf W
Urol Oncol; 2021 May; 39(5):299.e7-299.e14. PubMed ID: 33283758
[TBL] [Abstract][Full Text] [Related]
17. Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?
Seideman C; Canter D; Kim P; Cordon B; Weizer A; Oliva I; Rao J; Inman BA; Posch M; Herr H; Lotan Y
World J Urol; 2015 Sep; 33(9):1309-13. PubMed ID: 25420920
[TBL] [Abstract][Full Text] [Related]
18. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
Karaoglu I; van der Heijden AG; Witjes JA
World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
[TBL] [Abstract][Full Text] [Related]
19. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
